SCHEMBL2397625

SCHEMBL2397625

OCc1c2ccccc2c(Cl)c2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CYP2A6 P11509 5/20 0.38
CYP1A2 P05177 4/20 0.38
TSHR P16473 1/20 0.36
ALDH1A1 P00352 2/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
ELANE P08246 1/20 0.35
CTSG P08311 1/20 0.35
CTSA P10619 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35
CYP2C19 P33261 1/20 0.35
THPO P40225 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL488963 0.87 TSHR (0.45) MAOBCYP2A6CYP1A2TSHRALDH1A1
SCHEMBL29853841 0.87 TSHR (0.45) MAOBCYP2A6CYP1A2TSHRALDH1A1
SCHEMBL29440644 0.78 MAOA (0.58) MAOAMAOBCYP2A6CYP1A2TSHR
SCHEMBL147819 0.78 MAOA (0.58) MAOAMAOBCYP2A6CYP1A2TSHR
SCHEMBL14008502 0.77 MEN1 (0.41) CYP2A6CYP1A2TSHRALDH1A1LMNA
SCHEMBL10405240 0.77 L3MBTL1 (0.56) MAOAMAOBCYP2A6CYP1A2TSHR
SCHEMBL1072230 0.75 DRD4 (0.37) MAOBCYP2A6CYP1A2TSHRALDH1A1
SCHEMBL31283575 0.75 CYP3A4 (0.50) CYP2A6CYP1A2TSHRALDH1A1TP53
SCHEMBL12657296 0.75 HTR2A (0.54) MAOAMAOBCYP2A6CYP1A2ALDH1A1
SCHEMBL488903 0.75 CYP3A4 (0.50) CYP2A6CYP1A2TSHRALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
US-5663030-A A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT XEROX CORPORATION (US) 1997-09-02 US claimed
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 CN disclosed
US-8957212-B2 Photobase generator WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2015-02-17 US disclosed
CN-102232065-B Photobase generator WAKO PURE CHEM IND LTD 2014-11-05 CN disclosed
EP-2368875-B1 PHOTOBASE GENERATOR WAKO PURE CHEM IND LTD (JP) 2014-09-03 EP disclosed
CN-102232065-A Photobase generator WAKO PURE CHEM IND LTD 2011-11-02 CN disclosed
US-20110233048-A1 PHOTOBASE GENERATOR WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2011-09-29 US disclosed
EP-2368875-A1 PHOTOBASE GENERATOR Wako Pure Chemical Industries, Ltd. (JP) 2011-09-28 EP disclosed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US disclosed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US disclosed
US-5663030-A A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT XEROX CORPORATION (US) 1997-09-02 US disclosed
WO-1991005605-A1 CYCLODEXTRIN LABELS FOR IMMUNOASSAY AND BIOCHEMICAL ANALYSIS KOSAK KENNETH M (US) 1991-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110233048-A1 PHOTOBASE GENERATOR CYBA, CRY1, GNB1 MAOA 1413/4885MAOB 308/4885CYP2A6 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.